ATE541875T1 - Strategien zur freisetzung von wirkstoffen unter verwendung von mizellen und partikeln - Google Patents

Strategien zur freisetzung von wirkstoffen unter verwendung von mizellen und partikeln

Info

Publication number
ATE541875T1
ATE541875T1 AT06770201T AT06770201T ATE541875T1 AT E541875 T1 ATE541875 T1 AT E541875T1 AT 06770201 T AT06770201 T AT 06770201T AT 06770201 T AT06770201 T AT 06770201T AT E541875 T1 ATE541875 T1 AT E541875T1
Authority
AT
Austria
Prior art keywords
particles
strategies
micellars
release
active ingredients
Prior art date
Application number
AT06770201T
Other languages
English (en)
Inventor
Bali Pulendran
Niren Murthy
Robert H Pierce
Michael Heffernan
Jihua Hao
Marcin Kwissa
Original Assignee
Univ Emory
Georgia Tech Res Inst
Univ Rochester Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Georgia Tech Res Inst, Univ Rochester Medical Ct filed Critical Univ Emory
Application granted granted Critical
Publication of ATE541875T1 publication Critical patent/ATE541875T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G4/00—Condensation polymers of aldehydes or ketones with polyalcohols; Addition polymers of heterocyclic oxygen compounds containing in the ring at least once the grouping —O—C—O—
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L59/00—Compositions of polyacetals; Compositions of derivatives of polyacetals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AT06770201T 2005-05-10 2006-05-10 Strategien zur freisetzung von wirkstoffen unter verwendung von mizellen und partikeln ATE541875T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67948005P 2005-05-10 2005-05-10
US72009905P 2005-09-23 2005-09-23
PCT/US2006/018182 WO2006122223A2 (en) 2005-05-10 2006-05-10 Strategies for delivery of active agents using micelles and particles

Publications (1)

Publication Number Publication Date
ATE541875T1 true ATE541875T1 (de) 2012-02-15

Family

ID=37056867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06770201T ATE541875T1 (de) 2005-05-10 2006-05-10 Strategien zur freisetzung von wirkstoffen unter verwendung von mizellen und partikeln

Country Status (7)

Country Link
US (1) US20100062968A1 (de)
EP (1) EP1893661B1 (de)
JP (1) JP2008540558A (de)
AT (1) ATE541875T1 (de)
AU (1) AU2006243960A1 (de)
CA (1) CA2608086A1 (de)
WO (1) WO2006122223A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153110B2 (en) * 2006-11-22 2012-04-10 The University Of Tokyo Environment-responding siRNA carrier using disulfide-cross-linked polymeric micelle
AU2008239795A1 (en) * 2007-04-12 2008-10-23 Emory University Novel strategies for delivery of active agents using micelles and particles
US20100227415A1 (en) * 2007-07-24 2010-09-09 Iss Immune System Stimulation Ab Method and means for prediction of systemic lupus erythematosus susceptibility
CN102307586A (zh) * 2008-12-22 2012-01-04 都柏林伊丽莎白女皇神学院院长、研究员及专家协会 用于治疗自身免疫性疾病和炎性疾病的化合物及方法
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EA201171195A8 (ru) * 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
WO2010138192A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
EP2553019A1 (de) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modifizierte polymere zur freisetzung von polynukleotiden, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
WO2013036296A1 (en) * 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers
JP6464103B2 (ja) * 2013-03-11 2019-02-06 クリスタル・デリバリー・ビー・ブイ ワクチン接種用組成物
WO2014157150A1 (ja) * 2013-03-25 2014-10-02 日油株式会社 ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
WO2016010788A1 (en) 2014-07-15 2016-01-21 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Polyketal particles including a cpg oligodeoxynucleotide for the treatment of lung cancer
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
WO2017151922A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
CN106750333B (zh) * 2016-12-06 2019-09-24 长春斯菲尔生物科技有限公司 一种改性的聚缩酮pcadk及制备方法和医用用途
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
WO2020112913A1 (en) * 2018-11-26 2020-06-04 Duke University Compositions and methods for inducing scarring by peri-tumoral cells
EP3980784A1 (de) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulierungen und dosen von pegylierter uricase
CN115192524B (zh) * 2021-04-13 2023-08-29 杭州汉菁生物科技有限公司 一种包载链状难溶药物的聚合型胶束及制备方法和应用
WO2023086073A1 (en) * 2021-11-09 2023-05-19 Massachusetts Institute Of Technology Particles containing pollutant-capturing micelles and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
CA1211752A (en) * 1982-09-30 1986-09-23 Donald R. Kelsey Monomers and polyketal polymers from such monomers
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4765973A (en) * 1984-06-06 1988-08-23 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4950795A (en) * 1987-08-27 1990-08-21 Ciba-Geigy Corporation Oligomeric benzil ketals and their use as photoinitiators
DE60323936D1 (de) * 2002-01-14 2008-11-20 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US7790150B2 (en) * 2003-09-05 2010-09-07 The General Hospital Corporation Dual phase drug release system
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
WO2007098041A1 (en) * 2006-02-17 2007-08-30 Medtronic, Inc. Polyketal polymers, and methods of making and using same

Also Published As

Publication number Publication date
WO2006122223A3 (en) 2007-05-18
JP2008540558A (ja) 2008-11-20
WO2006122223A2 (en) 2006-11-16
CA2608086A1 (en) 2006-11-16
EP1893661B1 (de) 2012-01-18
US20100062968A1 (en) 2010-03-11
AU2006243960A1 (en) 2006-11-16
EP1893661A2 (de) 2008-03-05

Similar Documents

Publication Publication Date Title
WO2006122223A3 (en) Strategies for delivery of active agents using micelles and particles
HN2012001223A (es) Antagonistas de pcsk 9
MX2010004374A (es) Armazones proteinicos.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
BR112017004393A2 (pt) formulações de anticorpo
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EP4403197A3 (de) Injizierbare formulierungen zur organverstärkung
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
IN2012DN02735A (de)
CR11731A (es) Composiciones y procedimientos para su preparación y uso
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
MX338777B (es) Adjuvantes y metodos para utilizarlos.
AR057274A1 (es) Metodos para el tratamiento y la prevencion de fibrosis
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
UA104866C2 (uk) Імплантат октреотиду, який містить вивільняючу речовину
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
ATE547009T1 (de) Zusammensetzungen und verfahren zur förderung von körperfettverlust
WO2013111012A3 (en) Methods and compositions for therapeutic agents